High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial

The RAPP-01 clinical trial compared two adjuvant chemotherapies, doxorubicin plus docetaxel (arm A) versus doxorubicin plus cyclophosphamide (arm B), in 627 women with breast cancer. It stopped prematurely when three severe adverse events occurred among patients with febrile neutropenia (FN), all in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2015-09, Vol.153 (2), p.383-389
Hauptverfasser:	Callens, Céline, Debled, Marc, Delord, Marc, Turbiez-Stalain, Isabelle, Veyret, Corinne, Bièche, Ivan, Brain, Etienne
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Alleles Anthracyclines Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - complications Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cancer Cancer research Cancer therapies Chemotherapy Chromosomes Clinical Trial Clinical trials Cyclophosphamide DNA microarrays Febrile Neutropenia - epidemiology Febrile Neutropenia - etiology Female Genetic aspects Genetics Haplotypes Health risk assessment Humans Medicine Medicine & Public Health Middle Aged Neoplasm Grading Neoplasm Metastasis Neutropenia Oncology Organic Anion Transporters - genetics Pharmacogenetics Pharmacy Physiological aspects Polymorphism Polymorphism, Single Nucleotide Product development Randomized Controlled Trials as Topic Risk Single nucleotide polymorphisms Treatment Outcome Tumor Burden
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!